NCT04673201

Brief Summary

Purpose: To assess the safety and efficacy of Viscotrabeculotomy Versus trabeculectomy with MMC for the management of medically uncontrolled steroid induced glaucoma. Patients and methods: A retrospective review of 86 eyes of 67 patients with medically uncontrolled SIG who underwent either viscotrabeculotomy (VT) or trabeculectomy with MMC (Trab-MMC) at Mansoura Ophthalmic Center (Mansoura, Egypt) between January 2008, and December 2017 was conducted. Keywords: Steroid induced glaucoma, trabeculectomy, trabeculotomy and MMC.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 21, 2020

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

December 12, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 17, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

December 17, 2020

Status Verified

December 1, 2020

Enrollment Period

4 months

First QC Date

December 12, 2020

Last Update Submit

December 12, 2020

Conditions

Keywords

Steroid induced glaucomaTrabeculectomyTrabeculotomyMMC

Outcome Measures

Primary Outcomes (3)

  • Absolute success

    an IOP between 6 and 21 mmHg and /or IOP reduction greater than 35 % of baseline throughout the entire follow-up period without medications,

    4 years

  • qualified success

    an IOP between 6 and 21 mmHg and /or IOP reduction greater than 35 % of baseline throughout the entire follow-up period with medications,

    4 years

  • Failure

    not meeting the above criteria, or any return to the operating theatre for glaucoma reoperation, or loss of vision to no light perception or hypotony (IOP \<6 mmHg on 2 occasions after 3 months from the operation)

    4 years

Study Arms (2)

Viscotrabeculotomy group

ACTIVE COMPARATOR

Management of medically uncontrolled steroid induced glaucoma by viscotrabeculomy technique

Procedure: Viscotrabeculotomy Versus trabeculectomy with "MMC"

Trabeculectomy with "MMC" group

ACTIVE COMPARATOR

Management of medically uncontrolled steroid induced glaucoma by trabeculotomy with MMC

Procedure: Viscotrabeculotomy Versus trabeculectomy with "MMC"

Interventions

Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.

Trabeculectomy with "MMC" groupViscotrabeculotomy group

Eligibility Criteria

Age2 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Eyes with steroid induced glaucoma when IOP was persistently elevated despite maximal tolerated IOP-lowering therapy with potential or actual compromise of optic nerve structure (progressive optic nerve cupping) and/or function (deterioration of visual field testing)

You may not qualify if:

  • Oher causes and types of glaucoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura university ophthalmic center

Al Mansurah, Dakahlyia, 35516, Egypt

RECRUITING

Central Study Contacts

Amr M Abdelkader, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Retrospective comparative study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of ophthalmology

Study Record Dates

First Submitted

December 12, 2020

First Posted

December 17, 2020

Study Start

November 21, 2020

Primary Completion

April 1, 2021

Study Completion

June 1, 2021

Last Updated

December 17, 2020

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE

Locations